[HTML][HTML] Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities
SP Hack, AX Zhu, Y Wang - Frontiers in Immunology, 2020 - frontiersin.org
Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …
[HTML][HTML] Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects
S Tang, C Qin, H Hu, T Liu, Y He, H Guo, H Yan… - Cells, 2022 - mdpi.com
Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …
[HTML][HTML] Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses
Summary CD4 T follicular helper (TFH) cells support B cells, which are critical for germinal
center (GC) formation, but the importance of TFH-B cell interactions in cancer is unclear. We …
center (GC) formation, but the importance of TFH-B cell interactions in cancer is unclear. We …
Inferring gene expression from cell-free DNA fragmentation profiles
Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …
noninvasive cancer detection. Chromatin fragmentation features have previously been …
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III …
WZ Zhong, Q Wang, WM Mao, ST Xu, L Wu… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials. gov identifier: NCT01405079), a
randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved …
randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved …
Lower airway dysbiosis affects lung cancer progression
JCJ Tsay, BG Wu, I Sulaiman, K Gershner, R Schluger… - Cancer discovery, 2021 - AACR
In lung cancer, enrichment of the lower airway microbiota with oral commensals commonly
occurs, and ex vivo models support that some of these bacteria can trigger host …
occurs, and ex vivo models support that some of these bacteria can trigger host …
Deep learning reconstruction shows better lung nodule detection for ultra–low-dose chest CT
Background Ultra–low-dose (ULD) CT could facilitate the clinical implementation of large-
scale lung cancer screening while minimizing the radiation dose. However, traditional image …
scale lung cancer screening while minimizing the radiation dose. However, traditional image …
[HTML][HTML] Genomic mapping of metastatic organotropism in lung adenocarcinoma
Summary We analyzed 2,532 lung adenocarcinomas (LUAD) to identify the
clinicopathological and genomic features associated with metastasis, metastatic burden …
clinicopathological and genomic features associated with metastasis, metastatic burden …
[HTML][HTML] Immune checkpoint inhibitor-associated colitis: from mechanism to management
L Tang, J Wang, N Lin, Y Zhou, W He, J Liu… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies,
including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and …
including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and …
[HTML][HTML] ILT4 inhibition prevents TAM-and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR …
X Chen, A Gao, F Zhang, Z Yang, S Wang, Y Fang… - Theranostics, 2021 - ncbi.nlm.nih.gov
Abstract Rationale: Immune checkpoint inhibitors (ICIs) against the PD-1/PD-L1 pathway
showed limited success in non-small cell lung cancer (NSCLC) patients, especially in those …
showed limited success in non-small cell lung cancer (NSCLC) patients, especially in those …